Table 1.
Demographics, Underlying Conditions, and Pretransplant Conditioning Regimens of 57 Patients Who Received an Umbilical Cord Blood Transplant
| Demographic Information | n (%) |
|---|---|
| Female | 34 (59.6) |
| Age (years), mean ± standard deviation | 43.1 ± 13.6 |
| BMI (kg/m2), mean ± standard deviation | 26.3 ± 5.7 |
| Hematological Malignancy | |
| Acute leukemia or myelodysplastic syndrome | 39 (68.4) |
| Lymphomaa | 12 (21.1) |
| Multiple myeloma | 4 (7.0) |
| Chronic myeloid leukemia | 1 (1.8) |
| Myelofibrosis | 1 (1.8) |
| Prior Hematopoietic Cell Transplant | |
| Autologous stem cell transplant | 10 (17.5) |
| Umbilical cord blood transplant | 1 (1.8) |
| Infections Within Prior 6 Monthsb | 23 (40.4) |
| Bacteremiac | 12 (21.1) |
| Clostridium difficile infection | 9 (15.8) |
| Pneumonia | 5 (8.8) |
| Intraabdominal infection | 5 (8.8) |
| Urinary tract infection | 5 (8.8) |
| Respiratory viral infection | 1 (1.8) |
| Invasive aspergillosis | 5 (8.8) |
| Hepatosplenic candidiasis | 1 (1.8) |
| Conditioning Type | |
| Myeloablative | 31 (54.4) |
| Reduced-intensity | 26 (45.6) |
| Conditioning Regimen | |
| Total body irradiation | 54 (94.7) |
| Busulfan/fludarabine | 28 (49.1) |
| Cytarabine/fludarabine | 17 (29.8) |
| Cytarabine | 8 (14.0) |
| Otherd | 4 (7.0) |
| Antithymocyte globulin | 3 (5.3) |
| Rituximab | 3 (5.3) |
Abbreviations: BMI, body mass index.
aFollicular lymphoma (3), diffuse large B-cell lymphoma (3), marginal zone lymphoma (2), anaplastic large cell lymphoma (1), angioimmunoblastic T-cell lymphoma (1), Hodgkin lymphoma (2).
bMany patients had more than 1 infection.
c Enterococcus spp (3), Klebsiella pneumoniae (2), Escherichia coli (1), Staphylococcus aureus (3), Enterobacter cloacae (1), Micrococcus luteus (1), Streptococcus spp (2), Staphylococcus epidermidis (2).
dFludarabine/melphalan (1), etoposide (2), carmustine/etoposide/cytarabine/melphalan (1).